“…A number of neutrophil subpopulations have previously been identified through functional and phenotypic associations in various models, including but are not limited to human CD177 + (Hu et al, 2009;Silvestre-Roig et al, 2016;Wu et al, 2016;Zhou et al, 2018), olfactomedin-4 + (OLFM4) (Clemmensen et al, 2012), TCR-expressing (Puellmann et al, 2006), CD49d + VEGFR1 high CXCR4 high angiogenic (Christoffersson et al, 2012;Massena et al, 2015), CD63 + (Tirouvanziam et al, 2008), IL-13 + (Chen et al, 2014), CD49 + (Cheung et al, 2010;Tsuda et al, 2004), IL-17producing (Taylor et al, 2014), CD62L dim /CD16 bright and CD62L bright /CD16 dim (Pillay et al, 2012), immunosuppressive CD11c bright CD62L dim CD11b bright CD16 bright (Pillay et al, 2012), CD16 dim banded (Leliefeld et al, 2018), CD62L dim (Tak et al, 2017), mature CD10 + and immature CD10 - (Marini et al, 2017), and tumor- Neutrophils are now known to be important in cancer. Two tumor-associated neutrophil (TAN) subpopulations are present in tumors: pro-inflammatory antitumorigenic N1 neutrophils and pro-tumorigenic N2 neutrophils (Fridlender et al, 2009;Giese et al, 2019;Sionov et al, 2015). N1 TANs showed a more immunostimulatory mRNA profile than N2 neutrophils, expressing higher levels of TNF-α, CCL3, iNOS, and ICAM-1.…”